23 results about "Pro-apoptosis" patented technology

The invention provides a bacterial outer membrane vesicle presenting Stoppin peptide as well as a construction method and application of the bacterial outer membrane vesicle, and relates to the technical field of biological medicines. According to the invention, a fusion protein ClyA-Stoppin is firstly designed and synthesized, and the fusion protein ClyA-Stoppin is displayed on the surface of the bacterial outer membrane vesicle by using a genetic engineering technology, so that the engineered bacterial outer membrane vesicle W-Stoppin OMV for targeting presentation of Stoppin peptide is successfully constructed. The W-Stoppin OMV provided by the invention has a remarkable inhibition effect on invasion and migration of tumor cells and can be used for remarkably promoting apoptosis of the tumor cells. According to the present invention, with the Stoppin monopeptide, the problems of insufficient Stoppin cell penetrability and difficult intracellular delivery are effectively solved, compared with the Stoppin monopeptide, the Stoppin monopeptide shows the excellent anti-tumor effect, and the migration inhibition, the invasion inhibition and the apoptosis promotion effects on the tumor cells are significantly increased. The W-Stoppin OMV provided by the invention has huge application potential in the aspect of preparation of anti-tumor drugs.

The invention relates to a gene and a plasmid of a humpback perch apoptosis regulator Bad and application of the gene and the plasmid, and belongs to the field of molecular biology, and the sequence of cDNA nucleotide of the humpback perch apoptosis regulator Bad is as shown in SEQ ID NO.1. The invention also provides a construction method of an eukaryotic expression plasmid of the humpback perch apoptosis regulator Bad, and a construction method of the eukaryotic expression plasmid of the humpback perch apoptosis regulator Bad. It is verified that the constructed eukaryotic expression vector has an apoptosis promoting effect on humpback perch cells, and after the humpback perch apoptosis regulatory factor Bad eukaryotic expression plasmid is injected into a fish body, bacterial reproduction can be remarkably inhibited, and a remarkable immune protection effect is achieved.

The invention relates to the technical field of biological medicines, in particular to a polypeptide targeting B cell lymphoma cells, a targeting effect conjugate and application of the polypeptide and the targeting effect conjugate. Wherein the peptide chain length of the polypeptide targeting the B-cell lymphoma cells is 12 amino acids, and the polypeptide is selectively and specifically combined with the B-cell lymphoma cells. The targeting effect conjugate is formed by connecting polypeptide and pro-apoptotic peptide through a connecting peptide. The pro-apoptotic peptide can induce programmed death of target cells by destroying a mitochondrial membrane structure. The molecular weight of the polypeptide is small, the chemical synthesis process is simple, convenient and efficient, high consistency between different batches of products can be ensured in the synthesis process, and a guarantee is provided for subsequent quality control. The small molecular structure is also convenient for sequence optimization and terminal modification, can create extremely favorable conditions for subsequent structure-function relationship research and pharmaceutical development work, and is helpful for accelerating the research and development process of novel therapeutic drugs.

The invention relates to the technical field of microorganisms, and particularly discloses a lactobacillus plantarum R202448 and application thereof in resisting helicobacter pylori, the lactobacillus plantarum R202448 is preserved in China General Microbiological Culture Collection Center on June 27, 2025, and the preservation number is CGMCC NO. The lactobacillus plantarum is located in Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, West Beichen Road, Chaoyang District, Beijing, has a preservation number of CGMCCNO: 31101, and is classified and named as lactobacillus plantarum R202448. According to the plant lactobacillus R202448 and the metabolite thereof disclosed by the invention, on the basis of inhibiting an H.pylori biological membrane and reducing the activity of the H.pylori, the damage and apoptosis promoting effects of the H.pylori on gastric mucosa epithelial cells can be effectively inhibited, so that the occurrence of the H.pylori is effectively inhibited, and the functions of the gastric mucosa epithelial cells are protected.

The invention discloses a plant lactobacillus and application thereof in relieving aflatoxin B1 induced liver injury, and relates to the technical field of microorganisms. The lactobacillus plantarum disclosed by the invention is lactobacillus plantarum TY-1, and the preservation number of the lactobacillus plantarum TY-1 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 20251682. The lactobacillus plantarum TY-1 disclosed by the invention has the advantages that the lactobacillus plantarum TY-1 is a lactobacillus plantarum TY-1, and the preservation number of the lactobacillus plantarum TY-1 in the China Center for Type Culture Collection (CCTCC); the bacterial strain has bacteriostatic activity and better oxidation resistance, and can effectively reduce the level of proinflammatory factors in serum, down-regulate the relative expression of pro-apoptosis genes and reduce the apoptosis of liver cells, thereby effectively relieving the damage to the liver caused by exposure to aflatoxin B1.

The present invention relates to CD117 targeted LNP molecules for delivery of pro-apoptotic mRNA to hematopoietic stem cells (HSCs) and methods of use thereof for preconditioning a subject for hematopoietic stem cell therapy or to deplete the subject's HSC population for the treatment of a disease or disorder.

This invention relates to the fields of microbiology and biomedicine, and particularly to a strain of *Lactobacillus brittlemi* SYSU-32 and its application in tumor treatment. This invention cultured and isolated a strain of *Lactobacillus brittlemi* (SYSU-32). Limosilactobacillus pontis SYSU-32 was deposited on September 15, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 35919. This strain can increase CD8+ in the tumor microenvironment. + Infiltration of T cells and cytotoxic T cells inhibits the progression of colorectal cancer. Furthermore, the combination of *Lactobacillus bridgedii* SYSU-32 with the chemotherapy drug oxaliplatin enhances the pro-apoptotic effect of oxaliplatin, further inhibiting tumor progression and metastasis.

The application belongs to the technical field of biological medicine, and particularly relates to application of an imidazoquinazoline small-molecule compound or a pharmaceutically acceptable salt thereof shown in formula (I) in preparation of a drug for treating KRAS mutant gastrointestinal tumors, wherein R is as described in the claims and the specification. The imidazoquinazoline compound can selectively inhibit proliferation, migration and invasion of KRAS mutant gastrointestinal tumor cells, and induce cell cycle arrest and apoptosis. Specifically, the compound exerts an anti-tumor effect by inhibiting the binding of p-ERK2 and p53, restoring p53 transcriptional activity, and up-regulating the expression of a pro-apoptotic gene PUMA downstream of p53. The mechanism of action is different from that of traditional KRAS or MEK inhibitors, and provides a new treatment option for KRAS mutant gastrointestinal tumor patients.

The invention relates to the technical field of medicines, and particularly discloses a pharmaceutical composition based on an IRF7-PTEN signal axis and application of the pharmaceutical composition in spinal cord injury. According to the application, a plurality of spinal cord injury single cell sequencing data sets are integrated, and the interferon regulatory factor 7, namely IRF7, is screened and verified to be a key hub gene for regulating and controlling apoptosis of astrocytes. Knock-down IRF7 significantly inhibits astrocyte apoptosis induced by etoposide, and rotation IRF7 can reverse the effect. In mechanism, the IRF7 promotes cell apoptosis by negatively regulating a PTEN pathway, and the PTEN inhibitor SF1670 can block the IRF7 overexpression mediated apoptosis promoting effect. On the basis, the invention provides a pharmaceutical composition taking the signal axis as a target spot, and the active ingredient of the pharmaceutical composition can be an IRF7 inhibitor or a PTEN inhibitor; the invention also discloses application of the inhibitor in preparation of drugs for treating spinal cord injury. The application provides a new target spot and an effective intervention strategy for treatment of spinal cord injury.

The invention discloses a composite single-cell protein feed for improving anti-infection immunity of micropterus salmoides and application of the composite single-cell protein feed, and belongs to the technical field of feed preparation. The feed comprises composite single-cell protein for replacing 40-100% of fish meal, and the composite single-cell protein comprises chlorella and clostridium ethanol protein in a mass ratio of 1: (4-5). The compound single-cell protein is adopted to replace part of fish meal in the feed, so that the cost of the feed can be remarkably reduced, the anti-infection immunity of the micropterus salmoides to aeromonas hydrophila can be improved, expression down-regulation of a pro-apoptosis gene casp8 and an antigen presentation related gene mhci in the micropterus salmoides can be promoted, and the apoptosis resistance of the micropterus salmoides can be improved. The expression up-regulation of the anti-apoptosis gene bcl2l1 and the anti-ferroptosis gene gpx4a is promoted. In addition, the liver metabolism function of the micropterus salmoides can be improved, and lipid metabolism is promoted.

The invention relates to the field of treatment of neurodegenerative diseases, and discloses a method for treating ALS through intrathecal targeted drug delivery of an extremely low dose of KN93 after a disease is attacked, and the method comprises the following steps: screening ALS model objects showing disease symptoms; within 24 hours after the ALS model object is confirmed to be diseased, the KN93 pharmaceutical composition is applied to the space in the spinal cord sheath for a single time; and evaluating the curative effect of the ALS model object after the KN93 pharmaceutical composition is applied. In a treatment window period within 24 hours after an ALS model object is attacked, an extremely low dose of KN93 pharmaceutical composition is directly delivered to a spinal cord intrathecal gap in an intrathecal administration manner, so that the medicine can quickly enter cerebrospinal fluid circulation and is enriched in a central lesion target region in a targeted manner without penetrating through a blood brain barrier and a blood-spinal cord barrier; therefore, pathological excessive activation of CaMKII is specifically inhibited, and injury mechanisms such as neuronal excitatory toxicity, calcium overload and pro-apoptosis pathway mediated by CaMKII are blocked.

The invention provides application of amentotaxus biflavone in preparation of a medicine for treating bladder cancer, and provides application of amentotaxus biflavone in preparation of a medicine for treating bladder cancer, which has the advantages that by increasing the concentration of amentotaxus biflavone, the number of bladder cancer cells is gradually reduced, the cells are shrunk, nuclear shrinkage of different degrees is caused, the activity, proliferation, invasion and migration of bladder cancer T24 cells and bladder cancer 5637 cells are inhibited, and the bladder cancer is treated. The PI3K / AKT / NF-kappa B pathway promotes the expression of a pro-apoptosis gene Bax in bladder cancer cells, inhibits the expression of an apoptosis inhibitor gene Bcl-2, inhibits the proliferation of the bladder cancer cells by inducing G1 phase retardation of the bladder cancer cells, induces and reduces the expression of PI3K, AKT and NF-kappa B proteins in cell nucleuses through the PI3K / AKT / NF-kappa B pathway, and induces the apoptosis of the bladder cancer cells. The invention belongs to the field of medicine.

The invention provides brain polypeptide raw materials capable of benefiting intelligence and strengthening brain, functional food and a preparation method of the brain polypeptide raw materials, and belongs to the technical field of functional food. The preparation method comprises the following steps: S1, pretreatment; s2, performing primary hydrolysis: adjusting the pH value of the pre-hydrolysate to 6.5-7.5, adding neutral protease with the addition amount being 3.5-4.5% of the mass of the bovine brain protein, performing enzymolysis at 50-60 DEG C for 1-3 hours, and performing enzyme deactivation to obtain first hydrolysate; s3, second hydrolysis: adjusting the pH value of the first hydrolysate to 6.0-7.0, adding papain with the addition amount being 1.0-3.0% of the mass of the bovine brain protein, carrying out enzymolysis at 45-65 DEG C for 1.5-2.5 h, and carrying out enzyme deactivation to obtain a second hydrolysate; and S4, performing post-treatment to obtain the brain polypeptide raw material powder. The brain polypeptide raw material can significantly remove DPPH free radicals and ABTS free radicals, inhibit the activity of acetylcholin esterase, repair PC12 nerve cells, inhibit the expression of a pro-apoptosis gene Bax and promote the expression of an anti-apoptosis gene Bcl-2, jointly exert the effects of benefiting intelligence, strengthening brain and protecting cranial nerves, and can be used as a functional factor to be applied to a functional product for benefiting intelligence and strengthening brain.

The application belongs to the technical field of photocatalysts, and particularly relates to a titanium dioxide-based composite material and a preparation method and application thereof. The application provides a titanium dioxide-based composite material, which comprises titanium dioxide nanoflowers and sheet-like carbon nitride loaded on the titanium dioxide nanoflowers. By introducing carbon nitride into the composite material, visible light absorption and catalytic activity can be further improved, so that the consumption of glucose as a sacrificial agent in a high glucose microenvironment is promoted. The results of a photocatalytic glucose depletion experiment show that the titanium dioxide-based composite material provided by the application can effectively degrade glucose and produce a large amount of hydrogen under visible light irradiation, can reduce the pro-apoptotic effect of a high sugar environment on cells, promote cell proliferation and migration, and thus support the healing of a diabetic wound.

CAR T cells, wherein the CAR T cells have a knockout in at least one proapoptotic gene, including BAK, BAX, or both. Methods of producing CAR T cells that have a knockout in at least one proapoptotic gene. Pharmaceutical compositions comprising CAR T cells that have a knockout in at least one proapoptotic gene. Pharmaceutical compositions including methods of CAR T cells and methods of treatment using pharmaceutical compositions.

The invention relates to the technical field of gene therapy, in particular to a method for knocking out a Bax gene on the basis of an HEK293 cell line by utilizing a CRISPR / Cas9 technology, constructing a stable cell line expressed by foreign protein and improving the AAV packaging efficiency. The invention discloses a Bax2.6 cell strain. A pro-apoptosis factor Bax gene is knocked out from an HEK293T cell. Compared with a wild type HEK293T cell, the Bax2.6 cell strain provided by the invention shows higher cell activity under various stress conditions, the cell survival rate of the Bax2.6 cell strain is improved by at least 20% under the treatment conditions of small molecule inhibitors ZV-FMK, Nec-1, puromycin (Puro), cis-platinum (CDDP) and rotenone, and the Bax2.6 cell strain shows excellent environmental tolerance and production robustness. When the Bax2.6 cell strain provided by the invention is used for transient transfection and packaging of an adeno-associated virus (AAV) vector, the copy number of the obtained AAV virus can be up to 2 * 10 copies / mL, and the AAV packaging efficiency is improved by more than 10 times compared with that of a conventional HEK293T cell line.

The present invention discloses 6,7-dihydro-5H-pyrido[2,3-c]pyridazine, 1,2,3,4-tetrahydroquinoline, 1H-indole, 3,4-dihydro-2H-1,4-benzoxacin, 7H-pyrrolo[2,3-b]pyridin-1-yl, 5H,6H,7H,8H,9H-pyridazino[3,4-b]azepine derivatives and related compounds represented by Formula (I) as Bcl-xL protein inhibitors for use as pro-apoptotic agents for treating cancer, autoimmune diseases, or immune system disorders. Formula (I) In the description, preparations of exemplary compounds (e.g., Examples 1-221 on pages 113-354) and pharmacological studies with relevant data (e.g., Examples A-E, Tables 1-5 on pages 355-367) are disclosed. Exemplary compounds are 2-{6-[(1,3-benzothiazol-2-yl)amino]-1,2,3,4-tetrahydroquinolin-1-yl}-1,3-thiazole-4-carboxylic acid (Example 1) or, for example, 3-{1-[(adamantan-1-yl)methyl]-5-methyl-1H-pyrazol-4-yl}-6-{3-[(1,3-benzothiazol-2-yl)amino]-4-methyl-5H,6H,7H,8H-pyrido[2,3-c]pyridazin-8-yl}pyridine-2-carboxylic acid (Example 24).

This invention provides a brain polypeptide raw material with brain-boosting and intelligence-enhancing properties and its preparation method. The preparation method includes the following steps: S1, pretreatment; S2, first hydrolysis: adjusting the pH of the pre-hydrolysate to 6.5-7.5, adding neutral protease at 3.5-4.5% of bovine brain protein mass, hydrolyzing at 50-60℃ for 1-3 hours, and obtaining the first hydrolysate after enzyme inactivation; S3, second hydrolysis: adjusting the pH of the first hydrolysate to 6.0-7.0, adding papain at 1.0-3.0% of bovine brain protein mass, hydrolyzing at 45-65℃ for 1.5-2.5 hours, and obtaining the second hydrolysate after enzyme inactivation; S4, post-treatment, to obtain the brain polypeptide raw material powder. This brain polypeptide raw material can significantly scavenge DPPH and ABTS free radicals, inhibit acetylcholinesterase activity, repair PC12 nerve cells, inhibit the expression of the pro-apoptotic gene Bax and promote the expression of the anti-apoptotic gene Bcl-2, thus exerting a brain-boosting and intelligence-enhancing effect and protecting brain nerves.